These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases. Mader S; Kümpfel T; Meinl E Curr Opin Neurol; 2020 Jun; 33(3):362-371. PubMed ID: 32304439 [TBL] [Abstract][Full Text] [Related]
43. Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008‒2018: A nationwide, population-based cohort study. Boesen MS; Jensen PEH; Born AP; Magyari M; Nilsson AC; Hoei-Hansen C; Blinkenberg M; Sellebjerg F Mult Scler Relat Disord; 2019 Aug; 33():162-167. PubMed ID: 31276927 [TBL] [Abstract][Full Text] [Related]
44. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Mao Z; Lu Z; Hu X Neurology; 2014 Sep; 83(12):1122. PubMed ID: 25224530 [No Abstract] [Full Text] [Related]
46. Clinical features and long-term outcome of a group of Japanese children with inflammatory central nervous system disorders and seropositivity to myelin-oligodendrocyte glycoprotein antibodies. Hino-Fukuyo N; Haginoya K; Nakashima I; Sato DK; Takahashi T; Misu T; Fujihara K; Hirose M; Kakisaka Y; Uematsu M; Kobayashi T; Kure S Brain Dev; 2015 Oct; 37(9):849-52. PubMed ID: 25748628 [TBL] [Abstract][Full Text] [Related]
47. Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up. Piccolo L; Woodhall M; Tackley G; Juryńczyk M; Kong Y; Domingos J; Gore R; Vincent A; Waters P; Leite MI; Palace J J Neurol; 2016 Feb; 263(2):370-379. PubMed ID: 26668077 [TBL] [Abstract][Full Text] [Related]
48. Mechanisms for lesion localization in neuromyelitis optica spectrum disorders. Bradl M; Reindl M; Lassmann H Curr Opin Neurol; 2018 Jun; 31(3):325-333. PubMed ID: 29465432 [TBL] [Abstract][Full Text] [Related]
50. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders? Di Pauli F; Berger T Front Immunol; 2018; 9():2753. PubMed ID: 30555462 [TBL] [Abstract][Full Text] [Related]
51. Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. Popescu BF; Guo Y; Jentoft ME; Parisi JE; Lennon VA; Pittock SJ; Weinshenker BG; Wingerchuk DM; Giannini C; Metz I; Brück W; Shuster EA; Carter J; Boyd CD; Clardy SL; Cohen BA; Lucchinetti CF Neurology; 2015 Jan; 84(2):148-58. PubMed ID: 25503621 [TBL] [Abstract][Full Text] [Related]
52. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Narayan R; Simpson A; Fritsche K; Salama S; Pardo S; Mealy M; Paul F; Levy M Mult Scler Relat Disord; 2018 Oct; 25():66-72. PubMed ID: 30048919 [TBL] [Abstract][Full Text] [Related]
53. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status. Yoshimura S; Isobe N; Matsushita T; Yonekawa T; Masaki K; Sato S; Kawano Y; Kira J; J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):29-34. PubMed ID: 23038741 [TBL] [Abstract][Full Text] [Related]
54. Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder. You Y; Zhu L; Zhang T; Shen T; Fontes A; Yiannikas C; Parratt J; Barton J; Schulz A; Gupta V; Barnett MH; Fraser CL; Gillies M; Graham SL; Klistorner A Ophthalmology; 2019 Jun; 126(6):801-810. PubMed ID: 30711604 [TBL] [Abstract][Full Text] [Related]
55. [The role of myelin oligodendrocyte glycoprotein antibodies for detection of demyelinating optic neuritis]. Wei SH; Zhao Y Zhonghua Yan Ke Za Zhi; 2017 Nov; 53(11):874-877. PubMed ID: 29141393 [TBL] [Abstract][Full Text] [Related]
56. Possible clinical role of MOG antibody testing in children presenting with acute neurological symptoms. Musso G; Nosadini M; Gallo N; Sartori S; Seguso M; Plebani M Neurol Sci; 2020 Sep; 41(9):2553-2559. PubMed ID: 32242290 [TBL] [Abstract][Full Text] [Related]
57. Detection of Autoantibodies Against Myelin Oligodendrocyte Glycoprotein in Multiple Sclerosis and Related Diseases. Spadaro M; Meinl E Methods Mol Biol; 2016; 1304():99-104. PubMed ID: 25814289 [TBL] [Abstract][Full Text] [Related]
58. Brain lesion distribution criteria distinguish demyelinating diseases in China. Cai MT; Zhang YX; Zheng Y; Yang F; Fang W; Shen CH; Ding MP Ann Clin Transl Neurol; 2019 Oct; 6(10):2048-2053. PubMed ID: 31566925 [TBL] [Abstract][Full Text] [Related]